Literature DB >> 10768869

The surgical approach to the adrenal gland: a comparison of the retroperitoneal and the transabdominal routes in 326 operations on 284 patients.

S K Nagesser1, J Kievit, J Hermans, H M Krans, C J van de Velde.   

Abstract

BACKGROUND: To compare the results of adrenalectomy using a retroperitoneal and a transabdominal approach, especially for adrenal carcinoma and pheochromocytoma.
METHODS: A retrospective study was carried out at the Leiden University Medical Center. Charts of 284 patients who had undergone 326 adrenal operations between 1947 and 1995, including 44 patients with adrenal cancer and 60 patients with pheochromocytoma, were reviewed. The main outcome measures were operation time, blood loss, hospital stay and intra- and post-operative complications.
RESULTS: In patients who underwent adrenalectomy (ADX) using a retroperitoneal (RP) approach, duration of operation, intra-operative blood loss, hospital stay and post-operative morbidity compared favourably with those undergoing a transabdominal approach (TA-ADX). However, most of these differences could be explained by the more frequently benign nature and smaller size of the lesions in patients undergoing RP-ADX. However, blood loss remained lower after correction for confounding in all patients undergoing RP-ADX. In patients with larger adrenal lesions, adrenal cancer and pheochromocytoma, that would nowadays be held unsuitable for laparoscopic adrenalectomy, RP-ADX was associated with shorter operation time, less blood loss and less intra-operative complications.
CONCLUSION: Although laparoscopic adrenalectomy is the treatment of choice for small and benign adrenal lesions, larger lesions and/or adrenal malignancy require open adrenalectomy. In these cases the retroperitoneal approach is the preferred route.

Entities:  

Mesh:

Year:  2000        PMID: 10768869     DOI: 10.1093/jjco/hyd027

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Familial paraganglioma.

Authors:  A Cemal Umit Işik; Cihangir Erem; Mehmet Imamoğlu; Akif Cinel; Ahmet Sari; Gülden Maral
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-30       Impact factor: 2.503

Review 2.  Epinephrine-secreting cystic pheochromocytoma presenting with an incidental adrenal mass: a case report and a review of the literature.

Authors:  Cihangir Erem; Mustafa Kocak; Halil Onder Ersoz; Safak Ersoz; Yusuf Yucel
Journal:  Endocrine       Date:  2005-11       Impact factor: 3.633

Review 3.  Adrenal incidentalomas: surgical treatment in 28 patients and update of the literature.

Authors:  A B Porcaro; G Novella; V Ficarra; P Curti; S Z Antoniolli; H S Suangwoua; G Malossini
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

4.  Transperitoneal laparoscopic adrenalectomy: five years' experience with 35 patients.

Authors:  Altuğ Tuncel; Melih Balcı; Ersin Köseoğlu; Yılmaz Aslan; Özer Güzel; Tanju Keten; Dilek Berker; Serdar Göler; Ali Atan
Journal:  Turk J Urol       Date:  2013-12

5.  Laparoscopic transperitoneal adrenalectomy: Our initial results.

Authors:  Faruk Özgör; Murat Binbay; Mehmet Fatih Akbulut; Abdülmuttalip Şimsek; Murat Şahan; Ahmet Yalçın Berberoğlu; Ömer Sarılar; Ahmet Yaser Müslümanoğlu
Journal:  Turk J Urol       Date:  2014-06

6.  Safe retroperitoneal endoscopic resection of pheochromocytomas.

Authors:  Frits J Berends; Erwin Van Der Harst; Giuseppe Giraudo; Türkan Terkivatan; Geert Kazemier; Hajo A Bruining; Wouter W De Herder; H Jaap Bonjer
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

Review 7.  Early identification of patients with von Hippel-Lindau disease at risk for pheochromocytoma.

Authors:  J K Maranchie; M M Walther
Journal:  Curr Urol Rep       Date:  2001-02       Impact factor: 2.862

8.  Retroperitoneoscopic adrenalectomy for pheochromocytoma: comparison with open surgery.

Authors:  Ashok K Hemal; Rajeev Kumar; Mahesh C Misra; Narmada P Gupta; Sunil Chumber
Journal:  JSLS       Date:  2003 Oct-Dec       Impact factor: 2.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.